McN3716 (Methyl palmoxirate)
(Synonyms: Methyl palmoxirate; NSC359682) 目录号 : GC31427
McN3716 (Methyl palmoxirate) 是肉碱棕榈酰转移酶 I (CPT-1) 抑制剂。
Cas No.:69207-52-9
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor.
Inhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle[1].
[1]. Chen CT, et al. Inhibiting mitochondrial β-oxidation selectively reduces levels of nonenzymatic oxidative polyunsaturated fatty acid metabolites in the brain. J Cereb Blood Flow Metab. 2014 Mar;34(3):376-9.
Animal experiment: | Rats[1] Male Sprague Dawley rats are used. The rats receive ad libitum access to standard chow and water. At 15 weeks of age, six rats were subjected to either high-energy, head-focused microwave irradiation or CO2 asphyxiation. A separate group of 11 rats were implanted with a tail vein catheter (intravenous catheter 24 gauge/0.75 inch) and received either an intravenous injection of vehicle or 10 mg/kg of McN3716. Fifteen minutes after injection, rats were rapidly euthanized by high-energy, head-focused microwave irradiation (13.5 kW for 1.6 seconds) to avert ischemia for accurate quantification of in vivo basal levels of nonenzymatic auto-oxidative PUFA metabolites and enzymatically derived metabolites. Previously, we reported that this method reduced β-oxidation of fatty acid by 23% to 74%. McN3716 (Methyl palmoxirate, MEP) readily crosses the blood–brain barrier with a plasma half-life of 0.6 minute in the rat. The brain was excised and stored at -80°C for lipidomics profiling. |
References: [1]. Chen CT, et al. Inhibiting mitochondrial β-oxidation selectively reduces levels of nonenzymatic oxidative polyunsaturated fatty acid metabolites in the brain. J Cereb Blood Flow Metab. 2014 Mar;34(3):376-9. | |
| Cas No. | 69207-52-9 | SDF | |
| 别名 | Methyl palmoxirate; NSC359682 | ||
| Canonical SMILES | O=C(C1(CCCCCCCCCCCCCC)OC1)OC | ||
| 分子式 | C18H34O3 | 分子量 | 298.46 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3505 mL | 16.7527 mL | 33.5053 mL |
| 5 mM | 0.6701 mL | 3.3505 mL | 6.7011 mL |
| 10 mM | 0.3351 mL | 1.6753 mL | 3.3505 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet